Uniqsis announces substantial growth in flow chemistry market over last year

Uniqsis Ltd., specialists in flow chemistry, has announced a 50% growth in sales and a significant increase in trading profit for their business year ending 31st January 2017.

During the year – Uniqsis achieved strongest growth in North America and Europe with a notable increase in sales of its high performance FlowSyn integrated continuous flow reactor systems for pharmaceutical, nanomaterials and academic research applications.

Mr Paul Pergande (Managing Director) said:

The introduction of our entry-level FlowLab range of modular flow reactor systems and upgrades to the existing FlowSyn product range has delivered an increase in market share over the last year.

He added:

Moreover, our ethos of continuous technical innovation backed by informed responsive support has resulted in further orders from several major international organisations.

Reflecting upon technical developments in 2016, Dr Mark Ladlow (Chief Scientific Officer) commented:

Our ability to develop unique new products such as the Flow-UV™ in-line UV-Vis detector and offer optimised specialist FlowSyn systems has enabled us to provide customised solutions for end users in petrochemicals, flavours and fragrances and agrochemicals.

He added:

Investment made possible by our success last year is enabling Uniqsis to bring several exciting new products to market in 2017.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.